Research programme: GLP-1R modulatotrs - Carmot Therapeutics
Alternative Names: GLP-1R modulators - Carmot TherapeuticsLatest Information Update: 01 Feb 2024
At a glance
- Originator Carmot Therapeutics
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action Glucagon-like peptide-1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Type 2 diabetes mellitus
Most Recent Events
- 29 Jan 2024 Carmot Therapeutics has been acquired by Roche
- 10 Feb 2021 Research programme: GLP-1R modulatotrs - Carmot Therapeutics is available for licensing as of 10 Feb 2021. https://carmot-therapeutics.us/pipeline/
- 10 Feb 2021 Early research in Type 2 diabetes mellitus in USA (PO) prior to February 2021 (Carmot Therapeutics pipeline, February 2021)